COPENHAGEN (Reuters) - Danish biotech drugmaker Genmab's (CO:GEN) Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson (N:JNJ), has the potential to achieve annual peak annual sales as high as $13 billion (10.46 billion pounds), its chief executive told Reuters.
"It could work in other blood cancers as well as in solid tumours. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.
He acknowledged that $13 billion would be the most rosy scenario but said that Darzalex could "definitely" achieve more than $9 billion.
Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.